

Clinical trials of Telmisartan + ramipril

TrialResults-center www.trialresultscenter.org

1 hypertension

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|---------------------------------|
| Telmisartan + ramipril vs Ramipril | | | |
| ONTARGET/Tel+Ram, 2008 n=8502/8576 follow-up: 4.7 y | Telmisartan + ramipril versus Ramipril | patients with vascular disease or high-risk diabetes | Parallel groups double-blind |

More details and results :

- angiotensin-receptor blockers for hypertension in all diseases requiring ACEi (HF, CHD, HT,...) at <http://www.trialresultscenter.org/go-Q125>

References

ONTARGET/Tel+Ram, 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 [[18378520](#)]

Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009;120:1380-9 [[19770395](#)]

2 miscellaneous

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|---|
| telmisartan + ramipril vs ramipril | | | |
| ONTARGET (association vs ramipril), 2008 [NCT00153101] n=8502/8576 follow-up: 4.7y | telmisartan 80mg + ramipril 10mg daily versus ramipril 10 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage | Parallel groups double blind 40 countries |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| telmisartan + ramipril vs telmisartan | | | |
| ONTARGET (association vs telmisartan) , 2008 [NCT00153101] n=8502/8542 follow-up: 4.7y | telmisartan 80mg + ramipril 10mg daily versus telmisartan 80 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage | Parallel groups double blind 40 countries |

More details and results :

- angiotensin-receptor blockers for miscellaneous in all type of patients at <http://www.trialresultscenter.org/go-Q425>

References

ONTARGET (association vs ramipril), 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10;358:1547-59 [18378520]

ONTARGET (association vs telmisartan), 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10;358:1547-59 [18378520]

3 patients at high risk for cardiovascular events

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| telmisartan + ramipril vs ramipril | | | |
| ONTARGET (association vs ramipril) , 2008 [NCT00153101] n=8502/8576 follow-up: 4.7y | telmisartan 80mg + ramipril 10mg daily versus ramipril 10 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage | Parallel groups double blind 40 countries |
| telmisartan + ramipril vs telmisartan | | | |
| ONTARGET (association vs telmisartan) , 2008 [NCT00153101] n=8502/8542 follow-up: 4.7y | telmisartan 80mg + ramipril 10mg daily versus telmisartan 80 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage | Parallel groups double blind 40 countries |

More details and results :

- angiotensin-receptor blockers for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q97>
- angiotensin-Converting Enzyme Inhibitors for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q98>
- inhibition of the renin-angiotensin system (ACEI or ARB) for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q157>

References

ONTARGET (association vs ramipril), 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10;358:1547-59 [[18378520](#)]

ONTARGET (association vs telmisartan), 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10;358:1547-59 [[18378520](#)]

Entry terms: ramipril, Triatec, Altace, Delix, Ramace, Vesdil, Carasel, Acovil, Tritace, Zabien